IGF1 and diabetes mellitus: There are no robust predictors of the response to pegvisomant treatment, although pre-treatment GH and IGF-I levels, gender, body mass index, fat mass, presence of type 2 diabetes mellitus (DM), age and previous radiotherapy can influence the chance of disease control (23,24).